Unmet Need
- Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide, with increasing prevalence due to the global obesity and diabetes epidemic.
- NAFLD and Type 2 Diabetes (T2D) are interconnected metabolic disorders lacking safe, effective therapies.
- Current treatments offer limited efficacy and often present undesirable side effects.
Our Innovation
- Novel use of phytocannabinoids (CBD and CBG) to treat metabolic disorders including NAFLD, dyslipidemia, and T2D.
- Therapeutic effects demonstrated for:
- CBG alone
- Combination of CBD and CBG
- Multiple formulations tested, including co-administration and fixed-dose combinations.
Advantages
- Reduces liver fat accumulation (in vitro and in vivo models)
- Improves insulin sensitivity and glucose tolerance in high-fat diet models
- Lowers blood triglyceride and cholesterol levels, including LDL cholesterol
- Reduces body weight gain and overall fat mass in obese mouse models
- Anti-inflammatory effects by reducing hepatic TNFα and IL-6 expression
- Non-psychoactive treatment approach, leveraging the favorable safety profiles of CBD and CBG
Commercial Opportunity
- We are seeking collaboration with pharmaceutical and biotech companies targeting metabolic diseases, liver disorders, and nutraceuticals.
- Applications include:
- Therapeutic development for NAFLD, NASH, dyslipidemia, and T2D
- Nutraceutical or functional food products incorporating CBD and/or CBG
- Fixed-dose formulations for clinical testing and commercialization
